WEEKLY e-ALERT  [ PREMIUM EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Industry News
Wuxi AppTec Eyes U.S. Expansion amid Chinese Facilities Disruptions(2/20/2020 )  (Premium)
  WuXi AppTec looks to US sites to offset capacity lost due to ongoing closure of Chinese facility due to the coronavirus. With more than 10 facilities in China, WuXi AppTec is more exposed to the disruption stemming from the coronavirus outbreak than many other CROs.
Jinghua Pharma Drops Development of Two mAbs Licensed from Kadmon(2/20/2020 )  (Premium)
  Nantong-based Jinghua Pharmaceutical has called off the research and development of an anti-VEGFR2 monoclonal antibody (MAb) and an anti-PDL1 MAb that had been licensed from the American biotech Kadmon for the Greater China region back in 2015.
Vifor Pharma and Fresenius Kabi Create JV in China for IV Iron Portfolio(2/20/2020 )  (Premium)
  Vifor Pharma announced on February 20 a strategic partnership with Fresenius Kabi to create a new joint company based in China expanding its access to the second largest pharmaceutical market in the world.
Pharma and MedTech Outlook Clouded by Coronavirus Outbreak(2/20/2020 )  (Premium)
  The coronavirus outbreak in China is creating uncertainty for globally operating biopharmaceutical and medical device companies trying to forecast their 2020 performance as the healthcare system in the country focuses on stemming the virus, according to a S&P Global Market Intelligence article by Michael Gibney.
Teva Pharm Eyes Launch of Huntington's Drug in China This year(2/20/2020 )  (Premium)
  Teva Pharmaceutical Industries hopes to receive approval to launch its Huntington's treatment Austedo in China this year, the company's chief executive said on February 19.
U.S. FDA Suspends China Inspections, Warns of Potential Shortages(2/20/2020 )  (Premium)
  The U.S. Food and Drug Administration (FDA) has pulled inspectors from China amid the rapidly-spreading coronavirus and has warned Americans might face shortages of ¡°critical medical products¡± if the outbreak persists.
WuXi AppTec to Invest over $30M in CANbridge(2/17/2020 )  (Premium)
  WuXi AppTec is planning to invest over $30 million in Beijing-based biopharmaceutical firm CANbridge Pharmaceuticals, as the mainland leading biotech firm ramps up efforts to up stakes in China¡¯s orphan disease treatment market.
Global Antibiotics Supply Face Disruptions by Chinese Coronavirus Outbreak(2/17/2020 )  (Premium)
  The world could face a shortage of antibiotics if the pharmaceutical industry's supply problems posed by the coronavirus outbreak in China cannot soon be resolved, the head of a European business group in China warned on February 18.
Roche's Anticaner Alecensaa Approved in China for NSCLC(2/17/2020 )  (Premium)
  Roche has announced that the NMPA has granted marketing authorization for Alecensaa (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).
Pfizer's Revatio Approved in China for PAH(2/17/2020 )  (Premium)
  Pfizer announced that the NMPA has approved on February 5 its Revatio (sildenafil 20 mg) for the treatment of adult patients with pulmonary arterial hypertension (PAH). The product is China¡¯s first PDE-5 inhibitor approved for PAH to improve exercise ability and delay clinical worsening.
Hisun Receives Conditional Approval for Antiviral Favipiravir(2/17/2020 )  (Premium)
  Zhejiang Hisun Pharma received conditional approval from the NMPA for manufacture and marketing of favipiravir in China for new and recurring influenza in adults. The use of this product is restricted to situations when other antivirals for flu fail to work.
General Health
NHSA Releases Draft Interim Regulations for Designated Medical Institutions and Retail Pharmacies(2/19/2020 )  (Premium)
  The NHSA released on January 22 the drafts of two new regulations, the Interim Regulation for BMI Designated Medical Institutions and the Interim Regulation for BMI Designated Retail Pharmacies, for public comments.
Legal/IPR News
China to Fast-Track Biosecurity Law in Wake of Coronavirus(2/17/2020 )  (Premium)
  China plans to fast-track biosecurity legislation and elevate it to a national security issue in the wake of a coronavirus epidemic. A draft was submitted to the Standing Committee of the National Peoples Congress for review in October last year.
Product/R&D News
Terns Pharma Announces Positive Results of Phase 1 Trial of NASH Drug TERN-101(2/19/2020 )  (Premium)
  Terns Pharmaceuticals announced on February 19 the completion of a Phase 1 clinical study of TERN-101, an investigational farnesoid X receptor (FXR) agonist, which demonstrated all dose levels were well tolerated and achieved potentially therapeutic-level target engagement.
Gilead Struggles to Recruit Patients for Coronavirus Drug Trial in China(2/19/2020 )  (Premium)
  On February 5, 2020, it was reported that clinical trials of Gilead Sciences¡¯ remdesivir had launched in Wuhan, China. The experimental antiviral is to be evaluated as a treatment for 2019-nCoV, or what is now being called Covid-19.
Sanofi to Partner with BARDA for Coronavirus Vaccine Development(2/19/2020 )  (Premium)
  Sanofi Pasteur will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi will collaborate with the U.S. Biomedical Advanced Research and Development Authority (BARDA).
Several Drugs against Novel Coronavirus Already in Clinical Trials: Official(2/17/2020 )  (free)
  Several antiviral drugs have been applied in clinical trials against the novel coronavirus disease (COVID-19), and some have shown fairly good clinical efficacy, according to an official from MOST on Feb 15.
API/Bulk Drug News
India May Soon Impose Temporary Export Ban on Numerous Essential Medicines as Prices Soar(2/17/2020 )  (Premium)
  The ripple effects of the coronavirus outbreak in China is having global consequences. The price of paracetamol has spiked 40% in India, Bloomberg reported. Further, the cost of azithromycin, an antibiotic used for treatment of bacterial infections, has seen a rise of 70%.
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links